Safety trial of ECI301 for hepatocellular carcinoma patient treated with radio frequency ablation

Safety trial of ECI301 for hepatocellular carcinoma patient treated with radio frequency ablation - Safety trial of ECI301 for hepatocellular carcinoma patient treated with radio frequency ablation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020798

Enrollment

Registered

2016-01-29

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma patinets

Interventions

ECI301 (50, 100, or 150 microg/kg BW) will be injected daily for 5 days immediately after radio-frequency ablation treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patiente who are diagnosed as primary hepatocellular carcinoma by imaging. Perfomance status grad 0 or 1 in ECOG.

Exclusion criteria

Exclusion criteria: Patients who have severe disease in heart, kidnet, lung, hematopoiesis, coagulation system are excluded. Peatients who undego surgery, TACE, chmotherapy and radiation therapy within 4 weeks before the entry are excluded.

Design outcomes

Primary

Measure	Time frame
Safety of ECI301 for hapatocelluar carcinoma patients treated with radio-frequency ablation will be assessed in 4 weeks after the treatment according to CTCAE	—

Countries

Japan

Contacts

Public ContactNoriho Iida

Kanazawa University Hospital Department of gastroenterology

niida@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026